Trial Information

Matched Pair Analysis Comparing the Outcomes of Primary Breast and Nodal Diffuse Large B Cell Lymphoma in Patients Treated With R-CHOP; Consortium for Improving Survival of Lymphoma (CISL) Study

Primary breast lymphoma represents 1.7% to 2.2% of all extranodal non-Hodgkin's lymphoma.
Histologically, the diffuse large B cell lymphoma (DLBCL) is the most predominant subtype of
PBL. Previous studies in the pre-rituximab era have identified the worse outcomes in primary
breast DLBCL compared with nodal DLBCL. Few clinical studies have been reported for
investigating the efficacy of rituximab in patients with primary breast DLBCL. For
clarifying this, a large randomized trial comparing survival in patients with primary breast
DLBCL is required. However, the rarity of primary breast DLBCL makes large trial virtually
difficult in single center or study group. Additionally, retrospective studies for
evaluating the role of rituximab in primary breast DLBCL had bias according to the
difference of treatment period between CHOP and R-CHOP era. Thus, in attempt to clarify the
impact of rituximab on survival and patterns of progression in patients with primary breast
DLBCL, the investigators performed this matched pair analysis following strict matching
criteria in patients with primary breast DLBCL, who were identified from our previous
nation-wide survey, and nodal DLBCL, who were selected from the data registry of Korean
Society of Hematology Lymphoma Working Party, treated with R-CHOP regimen.